AM Solutions Brings Wet Blasting & Fully Automated Post-Processing To Formnext 2022
(13th October 2022, Untermerzbach, Germany) AM Solutions (a brand of the Rösler Group) is bringing…
Year: 2022
Device Management in Android TVs: Best Practices and Ideas for the Hospitality Industry
By Nadav Avni, Chief Marketing Officer at Radix Technologies Hospitality businesses failing to upgrade their…
Meta Connect 2022: Meta Quest Pro, More Social VR and a Look Into the Future
Takeaways Mark Zuckerberg unveiled Meta Quest Pro, the first in a new line of advanced…
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in…
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) — Event will be held on October…
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
Findings from this collaborative project with the University of Alberta using a unique surgical methodology…
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults…
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition…
Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused…
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE”…
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Topline results for PATHFNDR-1 study expected in Q3 2023 SAN DIEGO, Oct. 13, 2022 (GLOBE…
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
– Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million – Q3 2022 North…
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline Lack…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced…
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a…